No Detail Found!

Comparative Evaluation of COVID-19 Associated Mucormycosis (CAM) and Non-COVID-19-associated Mucormycosis (non-CAM)

Author(s)
Ebru Oruc Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey
Tugba Arslan Gulen Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey
Tuba Turunc Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey
Nur Yucel Ekici Department of Otorhinolaryngology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey
Nevzat Unal Department of Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey
Abstract
Objective: To compare COVID-19 associated mucormycosis cases (CAM) with non-COVID-19 associated mucormycosis (non-CAM) cases followed as in-patients. Study Design: Observational Study. Place and Duration of Study: Department of Infectious Diseases and Clinical Microbiology, Adana City Training and Research Hospital, Health Sciences University (HSU), Adana, Turkey, between January 2018 and March 2022. Methodology: Patients with a diagnosis of mucormycosis (proven and probable) were dichotomised as COVID-19 associated mucormycosis and non-COVID-19 associated mucormycosis cases. Both groups were compared for underlying malignancy, chemotherapy, antifungal therapy related side e ects and overall survival. Results: Of the 35 cases enrolled in the study, 17 (48.6%) had CAM and 18 (51.4%) had non-CAM. A statistically signi cant di erence was detected between non-CAM and CAM cases in terms of haematological malignancy, receiving chemotherapy, and antifungal therapy-related side e ects (p=0.019, p=0.019, and p=0.027 respectively). Steroid use was found as a risk factor for the diabetic CAM cases (p<0.0001). The di erence between the CAM and non-CAM cases in terms of overall survival was not statistically signi cant (p=0.088). Conclusion: Because of the ongoing COVID-19 pandemic and the increasing number of critical patients, treatment of COVID-19 should be performed cautiously in patients who have the risk of developing CAM, particularly those with diabetes and immunosuppression (haematologic malignancy, receiving steroid or chemotherapy, etc.) and these patients should be monitored closely.
Publication Details
Page(s) 153-157
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Diabetes Mellitus, Turkey, COVID-19, Diabetes mellitus, Diabetes mellitus, Mucormycosis, Mucormycosis associated with COVID-19
0

Citations

0

Downloads

53

Views